drugset / Trial / NCT02397499

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

NCT02397499

Phase 3 Completed 800 enrolled Neothetics, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Timeline

Start
2015-04
Primary completion
2015-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified

Indications

No indication recorded.